Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. (Nasdaq: CBLL) is a medical technology company that develops the Ceribell System, a point-of-care electroencephalography (EEG) platform for patients with serious neurological conditions in acute care settings. This news page aggregates company announcements, clinical and regulatory milestones, and financial updates that relate to CeriBell’s AI-powered brain monitoring technology.
Readers can find coverage of key regulatory events, such as FDA 510(k) clearances for the company’s next-generation Clarity® algorithm to detect electrographic seizures in pre-term neonates through adults and for its proprietary delirium screening and monitoring solution. The news feed also includes information on the FDA Breakthrough Device Designation granted to CeriBell’s Large Vessel Occlusion (LVO) stroke detection monitor, which uses existing Ceribell hardware and an AI-based algorithm to interpret EEG signals for early LVO stroke detection in hospitalized patients.
In addition to regulatory developments, CeriBell’s news includes quarterly financial results that distinguish between product and subscription revenue, updates on adoption of the Ceribell System in intensive care units and emergency rooms across the U.S., and disclosures about corporate agreements and intellectual property matters. Examples include supply agreements for EEG headbands, licensing arrangements with Stanford University, and patent-related legal actions.
Investors and healthcare professionals can also follow announcements about CeriBell’s participation in healthcare and medtech conferences, as well as board and governance updates. This page offers a centralized view of how the company’s point-of-care EEG platform, AI algorithms, and commercial activities are evolving over time, providing context for CBLL stock watchers and those tracking advancements in neurocritical care devices.
Ceribell (Nasdaq: CBLL) will participate in two investor conferences in early March 2026. CFO Scott Blumberg will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 at 1:00 p.m. PST / 4:00 p.m. EST.
CEO Jane Chao, Ph.D., and CFO Scott Blumberg will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 10:50 a.m. PST / 1:50 p.m. EST. Live and archived webcasts will be available in the company's Investor Relations section.
Ceribell (Nasdaq: CBLL) will release fourth quarter and full year 2025 financial results after market close on February 24, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live and archived webcast available in Investor Relations.
The Ceribell System is described as a portable, AI-powered point-of-care EEG platform and is FDA-cleared for detecting seizure and delirium in acute-care settings.
Ceribell (Nasdaq: CBLL) announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation on January 5, 2026 for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution for hospital patients.
The first-in-class monitor uses Ceribell’s existing point-of-care EEG hardware combined with an AI algorithm to interpret EEG signals for early LVO detection, and builds on recent 510(k) clearances for a neonatal seizure algorithm (Nov 2025) and a delirium screening solution (Dec 2025). The designation is supported by validation from prospective, multi-center studies using EEG data and clinical assessments and targets timely detection of in-hospital strokes, a population that represents up to 17% of U.S. strokes.
Ceribell (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and co‑founder will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 9:00 am PST / 12:00 pm EST.
A live and archived webcast of the presentation will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) announced FDA 510(k) clearance for its delirium monitoring solution on Dec 9, 2025, the first FDA-cleared device for continuous delirium screening at the bedside. The solution extends the Ceribell System to simultaneously support continuous seizure, electrographic status epilepticus (ESE), and delirium monitoring.
The delirium algorithm was validated in prospective studies of 225 adults in critical care. Ceribell has submitted a NTAP application to CMS to seek additional reimbursement for the new indication.
Ceribell (Nasdaq: CBLL) announced that the FDA granted 510(k) clearance on November 24, 2025 for its next‑generation Clarity algorithm to detect electrographic seizures from pre‑term neonates through adults. This clearance makes the Ceribell System the first and only AI‑powered point‑of‑care EEG cleared to detect seizures across all ages. The clearance was supported by EEG data from more than 700 patients and builds on a prior 510(k) clearance for a neonatal‑optimized headcap. The company positions the technology to enable faster bedside seizure detection in NICUs to reduce delays, transfers, and potential brain injury.
Ceribell (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and co-founder will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025.
The presentation is scheduled for 6:10 a.m. PST / 9:10 a.m. EST. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.
The session is scheduled for Thursday, November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST. A live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $22.6M, up 31% year-over-year; product revenue was $17.0M (+28%) and subscription revenue was $5.6M (+44%). Gross margin was 88% and gross profit was $19.9M. Operating expenses rose to $34.6M (+39%), driving a net loss of $13.5M (−$0.37 per share). Cash and marketable securities totaled $168.5M at quarter end. The company ended the quarter with 615 active accounts, appointed Erica Rogers to the board, and raised full‑year 2025 revenue guidance to $87M–$89M (~33%–36% growth).
Ceribell (Nasdaq: CBLL) will release its third quarter 2025 financial results after the close of trading on Tuesday, November 4, 2025.
Company management will host a conference call to discuss results at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Domestic callers can dial (800) 715-9871, international callers (646) 307-1963, and use access code 9394689. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.